Search Site
Home >> Signaling Pathways >> Apoptosis >> TNF-α >> Lenalidomide (CC-5013)
Related Biochemicals Related Antibodies

Lenalidomide (CC-5013)

Antitumor compound, inhibits angiogenesis

Lenalidomide (CC-5013)

Catalog No. A4211
Size Price Stock Qty
Evaluation Sample $28.00  All Inclusive In stock
50mg $90.00 In stock
100mg $160.00 In stock
250mg $210.00 In stock
500mg $350.00 In stock

All inclusive: Shipping and all other fees included

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Lenalidomide (CC-5013)

Related Biological Data

Lenalidomide (CC-5013)

Related Biological Data

Lenalidomide (CC-5013)

Biological Activity

Description Lenalidomide (CC-5013) is an inhibitor of TNF-α secretion with IC50 of 13 nM.
Targets TNF-α          
IC50 13 nM          

Lenalidomide (CC-5013) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Lenalidomide (CC-5013) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 191732-72-6 SDF Download SDF
Synonyms Revlimid,IMiD3,CC 5013,CDC-501,CDC 501
Chemical Name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
Canonical SMILES C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
Formula C13H13N3O3 M.Wt 259.3
Solubility Soluble in DMSO Storage Store at -20°C
Shipping Condition: Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

View Related Products By Research Topics

Background

Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. It has been extensively studied for the treatment of multiple myeloma and myelodysplastic syndrome as well as lymphoproliferative disorders including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. According to recent studies, Lnalidomide promotes and restores immune system function in CLL patients by inducing an overexpression of costimulatory molecules in leukemic lymphocytes to restore the humoral immunity and immunoglobulins production as well as improving the ability of T cells and leukemic cells to form synapses with T lymphocytes.

Reference

Ana Pilar Gonzalez-Rodriguez, Angel R. Payer, Andrea Acebes-Huerta, Leticia Hergo-Zapico, Monica Villa-Alvarez, Esther Gonzalez-Garcia, and Segundo Gonzalez. Lenalidomide and chronic lymphocytic leukemia. BioMed Research International 2013.